Is Orforglipron Legal? FDA, Compounding and WADA Status
Orforglipron's FDA status, compounding rules and anti-doping status, with a dated timeline of every change we track.
- FDA status
- Approved (Foundayo, Apr 2026)
- 1 Apr 2026
- PCAC vote
- Not reviewed
- not on the Jul 2026 PCAC agenda
- WADA
- Not listed
- 2026 Prohibited List
Current status
FDA approved (Foundayo, Apr 2026)Orforglipron is FDA approved (Foundayo, Apr 2026). Products sold as research chemicals are not the approved drug and are not checked by the FDA.
| Country | Status | Source |
|---|---|---|
| United States | ApprovedApproved by FDA as Foundayo (orforglipron), Eli Lilly, 1 April 2026, for chronic weight management in adults (label quote). | api.fda.govchecked 2 Oct 2026 |
Timeline
- Orforglipron approved as FoundayoApproval
Compounding and research-use sellers
- Category 2 is the FDA's list of bulk substances it flagged as raising significant safety concerns. Compounding pharmacies are not expected to compound from them while they are on it.
- The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which substances belong on the 503A bulks list that pharmacies may compound from. Its votes are advice; the FDA decides.
- "Research use only" products are sold outside these rules and are not checked by the FDA for identity, purity or dose.
Sport and drug testing
Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
Outside the US
Rules differ by country. What each regulator's own records show, with the date we checked:
| Country | Status | Source |
|---|---|---|
| United Kingdom | ApprovedListed on emc as Foundayo (orforglipron), Eli Lilly and Company Limited. | medicines.org.ukchecked 2 Oct 2026 |
| Canada | No approved product foundNo product found in a Health Canada Drug Product Database search for ingredient "orforglipron" on 2 Oct 2026. | health-products.canada.cachecked 2 Oct 2026 |
| Australia | No approved product foundNo approved product found in an ARTG search for "orforglipron" on 2 Oct 2026. | tga.gov.auchecked 2 Oct 2026 |
| European Union | No centrally authorised EU medicine foundEMA medicines list, searched 2 Oct 2026 | ema.europa.euchecked 2 Oct 2026 |
The April 2026 approval of Foundayo
FDA approved Foundayo (orforglipron) on April 01, 2026. Its release calls it the first new molecular entity approved under the Commissioner's National Priority Voucher pilot program.[9]
The Drugs@FDA record shows Foundayo as a tablet with prescription marketing status and an original approval date of 20260401.[3]
What the label and the release say it is for
The label indication is reducing excess body weight and maintaining weight reduction long term in adults with obesity, or with overweight plus a weight-related comorbid condition.[10]
FDA’s release describes it as a GLP-1 receptor agonist in tablet form taken orally once daily, with a starting dosage of 0.8 mg.[9]
Outside the US, and in sport
In the UK, the emc lists Foundayo 0.8 mg film-coated tablets.[4]
The Health Canada database search for orforglipron returned no active-ingredient records.[5]
Common questions
Is orforglipron FDA approved?
Yes. FDA approved it as Foundayo on April 01, 2026.[9]
Is Orforglipron legal to buy?
As an approved drug it requires a prescription in the US. Products sold online as research chemicals "not for human use" are not the approved drug.
Is Orforglipron banned by WADA?
No. GLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
Orforglipron FDA approval date?
The Drugs@FDA original approval date is 20260401.[3]
Is orforglipron approved in the UK?
It is listed on the emc, the UK medicines compendium, under the Foundayo name.[4]
Is orforglipron approved in Australia (TGA)?
The Australian Register of Therapeutic Goods search for orforglipron, saved with this site's sources, found no matching results.[6]
Is orforglipron approved by the EMA in the EU?
Searching the EMA medicines export generated 02/10/2026 (2746 rows) for orforglipron gives 0 matching rows, so it lists no centrally authorised orforglipron medicine; nationally authorised medicines are not in that list.[7]
More on Orforglipron
Sources
- 1FDA approves first new molecular entity under National Priority Voucher program (Foundayo, orforglipron), 1 Apr 2026U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3United States: Approved by FDA as Foundayo (orforglipron), Eli Lilly, 1 April 2026, for chronic weight management in adults (label quote).U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 4United Kingdom: Listed on emc as Foundayo (orforglipron), Eli Lilly and Company Limited.Electronic Medicines Compendium (UK) · 2026medicines.org.ukAccessed 2 Oct 2026
- 5Canada: No product found in a Health Canada Drug Product Database search for ingredient "orforglipron" on 2 Oct 2026.Health Canada · 2026health-products.canada.caAccessed 2 Oct 2026
- 6Australia: No approved product found in an ARTG search for "orforglipron" on 2 Oct 2026.Therapeutic Goods Administration (Australia) · 2026tga.gov.auAccessed 2 Oct 2026
- 7EMA medicines export (centrally authorised medicines) (searched 2 Oct 2026)European Medicines Agency · 2026ema.europa.euAccessed 2 Oct 2026
- 8Orforglipron approved as FoundayoFDA · 2026fda.govAccessed 2 Oct 2026
- 9Official web pageOfficial web page · web page
- 10FOUNDAYO prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.